Business
    Next Score View the next score

    Market Movers

    Myriad shares volatile on court ruling

    A complex Supreme Court ruling at first drove Myriad shares to a four-year high.
    AFP/GEtty Images
    A complex Supreme Court ruling at first drove Myriad shares to a four-year high.

    Shares of diagnostic test maker Myriad Genetics Inc. surged and then dove after the Supreme Court handed the company a partial victory in a battle over the validity of patents underlying its lucrative test for genes linked to high risk of breast and ovarian cancer. The Salt Lake City company sells a test for the BRCA 1 and BRCA 2 genes — the only test currently available because of its patents. They were challenged by a scientists group, leading to the Supreme Court’s review.

    Advertisement